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Summary 
Recent research has focused on the connections between the immune and skeletal systems and a 
new discipline has emerged named osteoimmunology which incorporates the complex 
interactions and overlap between the two systems.  The effect of B lymphocytes on bone 
metabolism is still poorly understood, although recent evidence suggests that B cells may 
particularly be implicated in the pathogenesis of bone loss in patients with rheumatoid arthritis 
(RA). Mature B cells have the potential to both inhibit and stimulate osteoclastogenesis via the 
secretion of specific cytokines; they have the ability to produce receptor activator of nuclear 
factor kappaB ligand (RANKL) a pro-osteoclastogenic cytokine, osteoprotegerin (OPG) an anti-
osteoclastogenic cytokine and transforming growth factor-β (TGF-β) a cytokine that has the 
ability to both induce and inhibit osteoclast formation. It is therefore not surprising that the 
existing evidence from both in-vitro and in-vivo studies is inconsistent. This review critically 
examines the role of B lymphocytes and key cytokines in the regulation of osteoblasto- and 
osteoclastogenesis in RA. 
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Introduction 
Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease 
characterized by symmetrical polyarthritis, joint destruction and extra-articular manifestations 
which can affect many different organ systems including: blood, skin, eyes, kidneys, heart and 
lungs. RA affects approximately 0.5-1% of the adult population worldwide [1]. The incidence of 
RA in England alone is 26,000 new cases per year, while its prevalence is believed to be more 
than 690,000 patients, resulting in a total annual cost of almost eight billion pounds [2]. RA is 
characterized by increased morbidity and mortality with considerable reduction in quality of life. 
While there has been progress in defining the etiology and pathogenesis of RA these are still 
incompletely understood. There is synovial inflammation, subsequent pannus formation and 
intra-articular bone erosions, which results in structural damage and it is this joint damage that is 
the major reason for disability in RA patients. In addition, the disease can affect the whole 
musculoskeletal system including; bones, cartilage, ligaments and tendons. There is both 
localized, peri-articular bone loss as well as generalized bone loss. Osteoporosis is one of the 
leading morbidities of RA and approximately one third of women with RA will develop a 
fracture within 5 years of their diagnosis [3]. These data clearly show that bone loss in RA is a 
significant public health issue; this review will focus on the importance of B cells in RA and 
their effects on the associated bone loss. 
 
B lymphocytes are typically characterized by their ability to produce antibodies, including 
autoantibodies. Since the discovery of rheumatoid factor (RF) and other citrullinated peptides, 
the role of B lymphocytes in RA has become more established and a number of treatments have 
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been developed to specifically target B cells. Tumor necrosis factor alpha (TNF-α) blocking 
agents were the first biological therapies to be approved for treating RA, however it is estimated 
that between 20 to 40 percent of patients fail to achieve a 20 percent improvement in the 
American College of Rheumatology (ACR) criteria. In addition, many patients lose response 
over time (secondary failure) and others develop side effects [4]. The relative success of 
specifically targeting TNF-α focused research into other components of the immune system in 
RA. Rituximab (RTX) is the first B cell targeted treatment originally used for the treatment of 
hematological malignancies such as lymphoma and leukemia. RTX is a chimeric monoclonal 
antibody directed against the CD20 molecule found on the surface of B cells, it depletes a large 
proportion of the B cell population with the exception of pro-B cells and mature plasma cells. 
RTX has proven to be highly successful and has renewed the interest in the role of B cells in RA 
[5]. Recent investigations have provided a great deal of evidence for a complex interaction 
between the immune and skeletal systems in physiological and pathological conditions. Results 
have shown that a number of cell surface receptors, cytokines and signaling pathways serve a 
critical role in both systems. In RA, the immune disturbance results in abnormal bone 
remodeling leading to bone loss. It is becoming clear that immune cells influence bone 
remodeling and vice versa. The interaction between immune progenitor cells and bone cells is 
facilitated by their proximity in the bone marrow where both osteoclastogenesis and 
hematopoiesis take place.  The role of the immune system, especially T cells, in inflammatory 
bone resorption and osteoclastogenesis is well established [6]. In addition to the indirect effects 
on bone turnover through the production of inflammatory cytokines that modulate 
osteoclastogenesis, T cells may also regulate bone turnover through direct cell-cell interaction 
with bone cells. On the other hand, bone cells may influence the immune responses as well as 
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accentuate bone turnover by affecting T cell activity through their ability to secrete different 
cytokines. Osteoclasts express major histocompatibility complex (MHC) class II molecules on 
their surface; they also activate CD40/CD40L signaling which is essential for T-cell and 
macrophage activation and many B cell functions [7]. Additionally, osteoclasts release abundant 
T cell chemo-attractants and can alter T cell responses by different mechanisms including: 
decreasing their development, inhibiting cytokine production by T cells such as TNF-α and 
interferon-gamma (IFN-γ) and by regulating their apoptosis [8]. 
 
The role of B cells in bone turnover in RA is still controversial. However, recent work by our 
group has demonstrated decreased bone resorption and increased formation following treatment 
with RTX, suggesting that B-cells may also be important in regulating bone turnover [9]. Other 
components of the immune system such as cytokines also play a critical role in the pathogenesis 
of RA induced bone loss. The most important cytokines involved in the disturbed bone 
imbalance in RA are receptor activator of nuclear factor kappa B ligand (RANKL) and 
osteoprotegerin (OPG) [10]. 
 
Overview of B cells 
B cell development 
B cells are formed in the bone marrow where hematopoietic stem cells differentiate initially 
through the pro-B, pre-B cell stage and into immature B cells which then complete their 
maturation in the spleen through three developmental stages; transitional type 1; type 2; then 
mature B cells [11]. Mature B cells then differentiate into antibody secreting plasma cells and 
memory B cells, also known as effector B cells.  B cells are subdivided into two main types; B1 
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cells are characterized by expressing mainly immunoglobulin M (IgM) and present in low 
numbers in the lymph nodes and spleen and more abundantly in the peritoneal and pleural 
cavities; while B2 cells are present in the peripheral circulation and the bone marrow [12]. 
Recent studies also indicate the coexistence of a distinct B cell subset called B regulatory cells 
(Bregs), which suppress immune function.  
 
Regulation of B cell function 
B cell regulation in physiological and pathological conditions is a complex mechanism under the 
influence of many cells. T cells are thought to play a major role in the activation of B cells by 
two mechanisms. The first through direct cell to cell contact in which the primary signal is the B 
cell receptor (BCR) binding to antigen and then presenting the antigen via MHC class II to the T 
cell receptor (TCR) on the surface of T cells, these in turn provide the B cells with the secondary 
signal via co-stimulatory binding of CD40L on T cells to CD40 on B cells to complete the B cell 
activation. The antigen-presenting function of B lymphocytes is thought to be relevant mainly in 
the late phase of infections and in secondary immune responses, due to the low number of 
clonogenic antigen-specific B cells that are present in homeostatic conditions [13]. The second 
mechanism by which T cells regulate B cell activity is by the release of lymphokines acting as 
growth factors for B cells [14]. Additionally, many cytokines and transcription factors contribute 
to the regulation of B cell development and activity, summarized in Table 1.  
 
Regulation of B cell homeostasis by bone cells 
There is growing evidence for a role of bone cells in hematopoiesis. B lymphopoiesis is 
maintained by osteoblasts in the bone marrow by their ability to support the differentiation and 
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proliferation of hematopoietic stem cells into all B cell stages. Culturing murine osteoblasts in 
vitro with primitive hematopoietic stem cells led to their differentiation into mature B 
lymphocytes. The authors showed that osteoblasts activated by PTH, stimulated B cell 
differentiation by signaling pathways that include vascular cell adhesion molecule 1 (VCAM-1), 
stromal cell-derived factor 1 (SDF-1) and IL-7. Furthermore, adding cytokines produced by 
stromal cells of non-osteoblastic origin such as c-Kit ligand, IL-6 and IL-3, led to myelopoiesis 
instead of lymphopoiesis [15]. Also, elimination of osteoblasts in vivo resulted in B cell 
depletion [16]. In a different murine model, blockade of osteoblastic PTH signaling by ablation 
of the G protein α subunit (Gsα), a class of G proteins that activate phospholipase C and 
participate in a variety of cellular signaling pathways, led to marked decrease in the numbers of 
B cells in the bone marrow but not the other hematopoietic cells [17]. 
 
Osteoclast activity is suggested to also have a critical role in B cell development in the bone 
marrow. Evidence has been obtained through studies in osteopetrosis. In this genetic condition 
there is a failure of bone resorption by osteoclasts and increased bone density, however the bone 
structure is poor and there is a tendency to fracture. Osteopetrosis is also characterized by 
reduced numbers of B cells, whether this decrease in B cell numbers is due to impaired bone 
marrow architecture and abnormal microenvironment, or if this is a direct effect of the disturbed 
function of osteoclasts on B cells in the bone marrow is unknown. Reports from the literature 
suggest that interactions between B cell precursors and bone marrow stromal cells are essential 
for B cell differentiation, but the role of osteoclasts in this process remains controversial. 
Recently, a mice model injected with zoledronic acid, an anti-resorptive agent, to artificially 
induce osteopetrosis was used to clarify the link between osteoclastic activity and B cell 
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development. The zoledronic acid led to suppression of osteoclastogenesis and a marked 
reduction in B cell numbers. The authors concluded that osteoclasts can modulate B-cell 
development in the bone marrow by controlling the bone microenvironment and the osteoblastic 
activity but they could not rule out the hypothesis that osteoclasts may directly affect B 
lymphopoiesis [18].  
 
Role of B cells in Rheumatoid Arthritis 
B cells have multiple functions in the pathogenesis of RA; they secrete auto-antibodies such as 
RF and the highly specific anti-cyclic citrullinated peptides antibodies (ACPA). RFs are 
antibodies directed against the Fc portion of IgG, along with ACPA they are thought to play a 
major role in the perpetuation of immune complexes suggested to be the main trigger for RA 
pathology. Additionally, B cells can process and present immune complexes and consequently 
activate complement thus contributing to autoimmune responses [19].  B cells are also able to 
secrete different pro-inflammatory cytokines and promote differentiation of follicular dendritic 
cells in secondary lymphoid organs [20]. In RA, effector B cells for example secrete TNF-α, IL-
6, IL-12 and IFN-γ [21, 22]. TNF-α plays a critical role in the pathogenesis of RA and its 
inhibition is currently one of the most successful treatments available for this disease. TNF-α has 
a wide variety of functions including; complement activation and stimulation of synovial 
fibroblasts and macrophages to secrete pro-inflammatory cytokines such as IL-6, prostaglandin 
E2 (PGE2) and matrix metalloproteinases (MMPs) inducing inflammation, cartilage and bone 
damage, in addition to transforming growth factor-beta (TGF-β), granulocyte/monocyte-colony 
stimulating factor (GM-CSF) and other growth factors that induce neovascularization and 
promote pannus formation characteristic of RA [23, 24]. IL-6, another major pro-inflammatory 
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mediator secreted by many cells including B cells, has a pivotal role in RA. IL-6 shares many 
effects with TNF-α, including stimulation of neovascularization, promotion of acute phase 
response, infiltration of inflammatory cells, synovial hyperplasia and damage to cartilage and 
bone [25]. B cells also produce IL-12 which stimulates the release of IFN-γ by T lymphocytes 
and natural killer (NK) cells and activates the T cell immune response leading to cellular 
infiltration, induction of inflammation, as well as cartilage and bone destruction [26]. IL-12 
levels in serum and in synovium correlate with disease activity in RA revealing the definite role 
of this mediator in RA pathology [27]. On the other hand, IFN-γ is found to have a dual action 
on chronic inflammation as it is capable of both inducing chronic inflammation and regulating 
immune responses [28]. 
 
 Interestingly, B cells can also secrete anti-inflammatory mediators such as IL-4 and IL-13. IL-4 
inhibits the activity of pro-inflammatory TNF-α, IL-1, IL-11 and IL-6, in addition to up-
regulating the inhibitory mediator IL-1 receptor antagonist in RA [29].  IL-13, similar to IL-4, is 
capable of suppressing the inflammation in RA [30]. 
 
Recently, a new subtype of regulatory B lymphocytes known as Bregs has been reported to 
regulate the immune system by producing the inhibitory cytokine IL-10. IL-10, also known as 
human cytokine synthesis inhibitory factor (CSIF), has pleiotropic effects in immune-regulation 
and inflammation. It down-regulates the proliferative responses and pro-inflammatory cytokine 
production by T helper cells, MHC class II antigen expression and co-stimulatory molecules on 
macrophages. Moreover Bregs can promote differentiation of T cells into regulatory IL-10 
producing T cells and hence permit vigorous immune suppression. Despite these anti-
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inflammatory effects, IL-10 has also been found to be an activator of B cell proliferation and 
antibody production. Moreover, Bregs were found to have other potential inhibitory mechanisms 
including secretion of the inhibitory cytokine TGF-β, interactions with Tregs and the production 
of regulatory antibodies [31]. 
 
Pathogenesis of bone loss in RA  
 
RA predisposes to both localized and generalized bone loss and increased fracture risk. This 
bone loss is multi factorial. Some of the drugs used to treat the condition can themselves cause 
bone loss such as glucocorticoids. Corticosteroids have been considered the cornerstone of the 
treatment of RA and most of the autoimmune diseases. Long-term use of corticosteroids is an 
established cause of generalized bone loss in RA. Nowadays, corticosteroid use has been 
minimized with the tendency to more aggressive use of disease modifying drugs (DMARDs) and 
the development of biological therapy.  RA can be significantly disabling leading to marked 
reduction in mobility and even loss of the patient’s ability to feed themselves which results in 
disuse atrophy of the muscles and a consequent reduction in bone mass. Muscle atrophy and joint 
destruction will also increase falls risk. Inflammation and autoimmunity are the main 
mechanisms of osteoporosis in RA. Chronic systemic inflammation leads to generalized 
osteoporosis and localized inflammation with regional osteoporosis [32]. It was therefore 
presumed that treating inflammation would be sufficient to stop bone loss in RA, but this view is 
now thought too simplistic. 
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Role of cytokines  
It has been well established that RA leads to increased bone resorption, but it has more recently 
been demonstrated that there is also substantially reduced bone formation. The increased bone 
resorption in RA has been explained by the increased osteoclastic activity under the effect of 
various inflammatory cytokines. Both RANKL-dependent and -independent osteoclastogenesis 
pathways are thought to play a role in the increased bone turnover in RA. Overproduction of 
RANKL by a wide range of cells, including osteoblasts, endothelial cells, T cells and B cells is a 
characteristic feature of RA. RANKL binds to its receptor RANK on the osteoclasts activating 
their proliferation and stimulating osteoclastogenesis. Human studies have revealed that RANKL 
plays a crucial role in the pathogenesis of bony erosions and peri-articular osteoporosis in RA. 
Synovial levels of RANKL positively correlate with disease activity and bone resorption in RA 
patients. RANKL in synovium is thought to be mainly secreted by B cells, synovial fibroblasts 
and T cells [33, 34]. Moreover, higher serum levels of RANKL were found in patients with high 
bone resorption markers and low bone mineral density of hips.  Also, levels of serum RANKL 
were able to predict joint destruction [35]. In another recent study, it was suggested that both 
increased RANKL and decreased OPG in peripheral blood is the main mechanism of 
osteoporosis in RA [36] 
 
Interestingly, many other cytokines such as TNF-α, IL-1, IL-4, IL-6, IL-7, IL-10, IL-11, IL-12, 
IL-13, IL-17, IL-18, IFN-γ and GM-CSF have variable effects on bone turnover and act via 
different mechanisms. TNF-α is a key player in RA osteoclastogenesis by both RANKL-
dependent and independent mechanisms. TNF-α blocking agents have recently been proven to 
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reduce the local and generalized bone loss in RA [37]. Moreover, TNF-α is thought to inhibit 
bone formation by increasing dickkopf-related protein 1 (Dkk-1) expression leading to 
sequestration of low-density lipoprotein receptor-related protein 5 and 6 (LRP5 & LRP6) 
receptors on the surface of osteoblasts; hence decreasing their binding to Wingless-Int (Wnt) 
proteins. Blocking the Wnt/beta-catenin signaling pathway leads to inhibition of osteoblasts 
differentiation and stimulation of their apoptosis resulting in decreased bone formation [38]. IL-1 
is capable of increasing bone resorption by increasing the release of MMPs and other degradative 
products and by promoting osteoclast differentiation and activation [39]. IL-1 can stimulate bone 
cells to secrete RANKL, IL-6 and IL-11; it can also induce bone loss by a RANKL-independent 
mechanism [40]. Moreover, IL-1, TNFα and IFN-γ can also suppress bone formation by 
inhibiting osteoblast collagen formation [41]. IL-6 induces osteoclastogenesis via the activation 
of T helper cells to secrete RANKL and IL-17 [42] and IL-17 is a major inducer of osteoclastic 
activity in inflammatory arthritis secreted by TH17 cells [43].  
 
IFN-γ functions as a modulator of bone turnover as it has a dual effect on osteoclasts; IFN-γ can 
block the formation of osteoclasts directly by inhibiting the differentiation of osteoclast 
precursors, but can also stimulate osteoclastogenesis indirectly by activating T cells to produce 
RANKL and TNF-α. It was presumed that the end function of IFN-γ is the induction of bone loss 
[44]. However, recently IFN-γ has been found to play a pivotal role in bone formation in vivo, 
IFN-γ knockout mice developed osteoporosis and suffered from a marked decrease in both 
osteoblast and osteoclast numbers [45]. 
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In contrast, other cytokines such as IL-4, IL-10, IL-12, IL-13, IL-18 and GM-CSF are protective 
of bone by either inhibiting osteoclastogenesis, or stimulating bone formation by osteoblasts. IL-
4 can suppress bone resorption and promote bone formation through its ability to inhibit the 
osteoclastogenic cytokines TNF-α, IL-1, IL-6 and IL-11 in RA. Additionally IL-4 and IL-13 can 
stimulate osteoblasts and suppress prostaglandin E2 (PGE2) synthesis [46]. IL-10 is secreted by 
many cells, primarily monocytes and to a lesser extent by lymphocytes, and is known to have an 
immunoregulatory effect in RA. It is presumed that it may have an anabolic effect on bone 
turnover by decreasing the production of TNF-α, IL-1, GM-CSF and the expression of HLA 
class II by monocytes [47]. Moreover, IL-10 is able to suppress the inflammatory effects of 
TH17 cells and promote the immunoregulatory Treg formation in RA patients resulting in the 
inhibition of osteoclast activity [48]. GM-CSF has been thought to inhibit osteoclast formation 
and activity; nevertheless the results of in vivo studies are conflicting [49]. IL-12 is capable of 
inhibiting osteoclastogenesis through its ability to stimulate immune cells particularly T cells and 
dendritic cells to secrete IFN-γ [50]. IL-18 is capable of inhibiting osteoclast formation by the 
ability to stimulate the release of GM-CSF by T helper cells [51]. Additionally, it has recently 
been reported that IL-18 can inhibit TNF-α mediated osteoclastogenesis in vivo by a T cell 
independent mechanism [52].  
 
 On the other hand, decreased bone formation in RA has been suggested to be mainly due to 
increased expression of Dkk-1. In a mouse model of RA, inhibition of Dkk-1 by a neutralizing 
antibody led to a reversal of bone erosion and resulted in new bone formation although no 
change in markers of inflammation was noted [53].  
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The role of T cells  
T cells are involved in most of the autoimmune diseases including RA. For many decades RA 
was considered to be a T-cell dependent disease as evidenced by large numbers of CD4+ T cells 
infiltrating the synovial tissues of RA patients [54]. T cells are activated by antigen presenting 
cells and trigger the immune response by secreting a wide range of inflammatory cytokines and 
thereby activating the whole immune system. T cells are a major source of RANKL and TNF-α 
and are therefore capable of regulating bone turnover in RA by activating osteoclastogenesis 
[55]. On the other hand, T cells may have an inhibitory effect on osteoclastogenesis by 
increasing OPG production by a mechanism that involves increased vitamin D3 activity [56]. T 
helper1 (Th1) cells produce IFN-γ and IL-2 and activate cell mediated immune response, 
whereas the T helper2 (Th2) subset produces IL-4 and stimulates humoral immunity. Imbalance 
between these two subsets results in inappropriate production of their respective cytokines and 
was found to be correlated with disease activity [57]. Despite the inflammatory effects of T cells 
in RA, there is also a protective subset named regulatory T cells (Tregs) which have anti-
inflammatory and bone protective effects. They act by regulating both type 1 and type 2 helper T 
cells [58]. Notably, both Tregs and CD8+ T cells have anti-osteoclastogenic effects [59]. 
However in RA it is still not established if there is a defect in the number or function of Tregs 
and whether this defect is directly related to RA osteoporosis. Interestingly, TNF-α has been 
found to suppress the Tregs response and this might be another mechanism by which TNF 
blocking agents act to control the disease activity and bone turnover in RA [60]. A third type of 
helper T cells, Th17 cells, has recently been implicated in RA bone loss. Th17 cells secrete IL-17 
which is capable of inducing osteoclastogenesis resulting in bone damage [61]. Additionally, T 
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cells are capable of interacting either directly with osteoblasts and osteoclasts or indirectly via 
stimulating dendritic cells and B cells [62]. 
 
 
The role of B cells in bone loss in RA 
 
Crosstalk between bone cells and B lymphocytes is bidirectional; bone cells can regulate the 
development and maturation of B cells and B cells can regulate both osteoblastic and osteoclastic 
activity. The mechanisms that underlie these interactions are only partially understood as is the 
precise role of B cells in bone turnover. B cells have the capacity to both stimulate and inhibit 
bone turnover by direct and indirect mechanisms (Figure 2). Additionally, B cells appear to be 
capable of affecting bone formation and resorption under different physiological and 
pathological conditions.  
 
B cells and cytokines 
Mature B cells secrete a number of different cytokines; including RANKL a key cytokine 
involved in bone breakdown and its inhibitor OPG, this mechanism works correctly under 
normal physiological conditions. The bone protective role of B cells is mainly achieved through 
OPG production. In RA this balance is disturbed by the increased B and T cell activity, leading 
to a marked increase in the production of RANKL by both cells in addition to other pro-
inflammatory cytokines such as TNF-α. This shifts the bone turnover balance towards bone loss.  
In an RA human model, the cytokine messenger-RNA expression by CD4 and CD8 T cells, B 
cells, macrophages and neutrophils was evaluated to identify the source of RANKL in the 
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synovial fluid and peripheral blood. B cells appeared to be a major source of RANKL in RA 
[33]. In addition to the bone specific cytokines mentioned above, other cytokines secreted by B 
cells can affect bone turnover and can either induce bone formation or bone resorption. TNF-α 
and IL-6 for example are pro-osteoclastogenic, while TGF-β, IL-4, IL-10, IL-12 and IL-13 are 
pro-bone formation. Additionally, B cells secrete IFN-γ which has both bone resorption and bone 
formation effects. However, the net effect of these variable B cell cytokines seems to differ in 
physiological and different pathological conditions [63]. 
 
B cells and osteoclasts  
 B cells are able to stimulate, both directly and indirectly, the conversion of monocytes to active 
osteoclasts. More interestingly, studies have shown that osteoclasts and B-lymphocytes may both 
arise from pro-B cells. Pro-B cells from osteopetrotic mice for example, expressed markers from 
the B-lymphoid (CD19, CD43 and CD5) and the myeloid (F4/80) lineages. When stimulated 
with RANKL and M-CSF, these cells could grow into osteoclasts, while they were able to 
differentiate into B cells when stimulated by IL-7 [64]. Furthermore, B cells have been found 
capable of transforming into osteoclasts. Recently it has been found in a murine model that a 
subset of CD19+ B lymphocytes named B1 cells, can differentiate into mononuclear phagocytes 
forming osteoclast-like multinucleated giant cells. These cells express RANK and the 
macrophage colony-stimulating factor receptor (M-CSFR) and when stimulated with RANKL 
and M-CSF, these cells transformed into tartrate resistant acid phosphatase (TRAP) positive 
osteoclasts and have osteoclastic properties leading to the formation of lacunae when allowed to 
grow on a calcium phosphate analog. Deficiency of B1 cells in these mice resulted in failure of 
bone resorption. Moreover, reconstitution of these cells resulted in an increase of 
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osteoclastogenesis [65]. In a human model of multiple myeloma, nuclei of malignant B cells 
were found in osteoclasts which might suggest that myeloma cells can differentiate into 
osteoclasts explaining the mechanism of increased osteoclastogenesis in these patients [66]. 
Additionally,  deletion of any of the transcription factors Ebf-1, paired box protein 5 (Pax5) and 
PU.1, which are essential for B cell development, resulted in marked changes in bone turnover in 
vivo. The transcription factor PU.1 is a protein encoded by the SPI1 gene; it is a specific factor 
for gene expression during myeloid and B-lymphoid cell development. Levels of PU.1 positively 
correlated with osteoclastic differentiation in vitro and deletion of PU.1 in vivo led to the arrest 
of osteoclast and macrophage differentiation [67]. More recently, reduction in PU.1 activity 
resulted in impaired B-cell development [68]. Ebf-1 deficiency in mice, another key regulator of 
B cell development, led to increased osteoclastogenesis and impaired B cell development, but 
despite this there was an overall increased bone mass. The authors explained that the mechanism 
of increased bone balance was the concomitant increase in the numbers and activity of 
osteoblasts. However, there is a hypothesis that B cell depletion may share in this anabolic effect 
on bone [69].  
 
Effect of B cell deficiency on bone 
It appears that too few B-cells can also be a problem and may result in bone loss. For example, in 
one murine model B cell deficiency resulted in marked osteopenia, this was explained by the 
resulting decrease in the amount of OPG that would have been produced by B cells.  In a 
different study, PAX5 deficient mice showed a loss of B cells and increased bone turnover from 
a dramatic rise in the numbers of osteoclasts together with a mild reduction in osteoblast 
numbers. The result was a marked decrease in bone volume, specifically trabecular bone. 
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However, they could not explain whether the resulting osteopenia was due to the decreased 
osteoblastic activity or the increased osteoclastogenesis or a combination of both [70]. 
New clinical evidence  
Data generated by our group demonstrated significant changes in bone turnover following B-cell 
depletion with RTX in RA patients, namely a decrease in bone resorption as evidenced by a 
marked decrease in beta-crosslaps (βCTx) and an increase in bone formation demonstrated by a 
rise in procollagen type 1 amino-terminal propeptide (P1NP). This suggests that there was a 
positive effect on bone metabolism as a result of B cell depletion therapy, which might result in 
an improvement in bone density and decreased fracture risk in RA patients. This effect may be 
due to remission of the disease activity, a reduction of the inflammatory process, improved 
general condition and therefore increased physical activity or may be due to a direct anti-
resorptive effect of the B cell depletion on bone cells or indeed a combination of all of these 
factors [9]. Further studies on larger cohorts are required to determine the exact mechanism of 
how B cells affect bone turnover. 
Future perspective 
The B cell is a tempting target for the treatment of bone loss mediated by RA. Future research 
will explore the underlying mechanisms of how B cells affect bone metabolism, this is critical 
for preventing and treating osteoporosis induced by RA. This knowledge may be a useful 
indicator of future disease course and have the potential to give clinicians valuable information 
about an individual patient’s response to treatment. Such understanding may also give insights 
into the pathophysiology of osteoporosis and other metabolic bone disorders.  
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Key	Issues	
	
Rheumatoid	arthritis	definition	and	epidemiology	
• RA	 is	 a	 chronic,	 systemic,	 inflammatory	 autoimmune	 disease	 characterized	 by	 symmetrical	
polyarthritis,	joint	destruction	and	extra-articular	manifestations.	
• Joint	damage	contributes	to	disability	in	RA	and	the	associated	life	time	treatment	costs	and	loss	
of	productivity	represent	a	substantial	economic	burden.	
	
Interaction	between	the	immune	and	skeletal	systems	
	
• The	 interaction	between	the	 immune	cells	and	bone	cells	 is	 complex.	This	might	 include	direct	
cross	talking	through	their	proximity	in	the	bone	marrow	as	well	as	indirect	signals	via	different	
cytokines.	
	
Overview	of	B	cells	in	RA	
• B	cells	develop	in	the	bone	marrow	from	haematopoietic	stem	cells.	
• B	cells	play	a	critical	role	in	the	pathogenesis	of	RA	by	various	mechanisms.	
• B	cell	regulation	is	complex	and	under	the	influence	of	many	cells,	cytokines	and	other	factors.	
	
Pathogenesis	of	bone	loss	in	RA	
	
• RA	 induced	 osteoporosis	 is	 multi	 factorial	 with	 various	 components	 of	 the	 immune	 system	
participating	in	its	pathogenesis	including	cytokines,	T	cells	and	B	cells.	
		
The	role	of	B	cells	in	bone	loss	in	RA	
• Crosstalk	between	bone	cells	and	B	lymphocytes	is	bidirectional.	
• B-lymphocytes	 have	 the	 capacity	 to	 both	 inhibit	 and	 stimulate	 osteoclastogenesis	 by	 different	
mechanisms.	
• RANKL	 and	 OPG	 remain	 the	 key	 players	 in	 the	 pathogenesis	 of	 osteoporosis	 in	 RA	 but	 other	
mediators	and	cells	may	also	be	involved.	
• B	lymphocytes	have	a	role	in	bone	formation	in	addition	to	bone	resorption.	
• B	cells	have	a	significant	effect	on	bone	turnover	but	whether	the	net	effect	is	towards	formation	
or	resorption	is	still	controversial	and	may	well	depend	on	the	circumstances.	
• B	cell	depletion	therapies	may	have	a	beneficial	effect	on	bone	loss.		
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Table 1: Factors affecting B cell development 
Factor Effect 
BAFF (B lymphocyte stimulator 
(BLyS)) 
Protein belonging to the TNF superfamily that  activates B 
cell differentiation; was found higher in RA compared to 
controls [71] 
APRIL 
Activator of B cell differentiation that has been found 
higher in RA compared to controls [71] 
Bruton’s tyrosine kinase (Btk) 
Activator of B cell differentiation; Its absence led to 
impaired B cell responses and reduced immunoglobulin 
levels [72] 
RANK 
Essential for B cell maturation and development; Its 
deficiency in mice resulted in failed B cell maturation [73] 
IL-7 
Essential cytokine for B cell development; Its deficiency 
leads to blockade of the transition between the Ly6D− and 
the Ly6D+ stages of B cell development [74] 
Neurotransmitter receptors 
(dopamine receptor 2 and 
acetylcholine receptor) 
Essential components for B cell development and were 
found to be over expressed in RA B cells compared to 
healthy individuals [75] 
Early B cell factor-1 (EBF-1) 
Protein needed for early B cell development that determines 
the subset fate of early B cells; Its deficiency led to arrested 
B cell development and maturation [76] 
Paired box protein (PAX5) 
Essential protein for B cell differentiation; Its deficiency 
led to arrested B cell development and maturation [77] 
PU.1 
A member of the ETS domain transcription factors that 
regulate the development of B lineage cells; Its deficiency 
impedes B cell proliferation [78] 
Ikaros family zinc protein 1 
Transcription factor encoded by the Ikaros gene (Ikzf1);  Its 
deficiency led to a complete failure of B cell development 
[79] 
22	
	
 
 
 
 
 
+?	
	
+?	
D
iff
er
en
tia
te
	in
to
		
	 Di
ff
er
en
tia
te
	in
to
		
B	cell	
	
B	cell	MSC	
	
MSC	
OC	
	
OC	
Monocytes	
Macrophage	
	
Monocytes	
Macrophage	
-	
	
-	
+	
	
+	OPG/	TGF-β	
	
	
OPG/	
TGFβ	
	
-	?	
	
-	?	
 
	
 
D
ifferentiate	into		
	D
ifferentiate	into		
	
	
	
CSF-M/	RANKL/	
TNF-α	
	
	
CSF-M/	RANKL/	
TNFα	
	
OB	
	
OB	
			+			RANKL	
	
	
			+			RANKL	
	
+			RANKL	
	
+			RANKL	
Figure 1: Effect of B cells on bone cells 
	
Figure	2:	Effect	of	B	cells	on	bone	cells	
Stimulatory signal          
Inhibitory signal              
Differentiate into           
OB osteoblast, OC osteoclast, MSC mesenchymal stromal cell, RANKL receptor activator of nuclear factor kappaB ligand, OPG osteoprotegerin, 
TGF-β transforming growth factor-beta, TNF-α tumour necrosis factor- alpha. 
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